Exact Sciences Corp (OQ:EXAS)

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Company Contact
Address: 5505 Endeavor Lane
MADISON WI 53719
Tel: N/A
Website: https://www.exactsciences.com
IR: See website
<
Key People
Kevin T. Conroy
Chairman of the Board, President, Chief Executive Officer
Jeffrey Thomas Elliott
Chief Financial Officer, Chief Operating Officer, Executive Vice President
Aaron Bloomer
Executive Vice President - Finance
Sarah Condella
Executive Vice President - Human Resources
James Michael John Herriott
Senior Vice President, General Counsel, Company Secretary
Brian Baranick
General Manager - Precision Oncology
Jacob Orville
General Manager - Screening
Everett V. Cunningham
Chief Commercial Officer
 
Business Overview
Exact Sciences Corporation is a global advanced cancer diagnostics company. The Company provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. The Company is focusing its research and development efforts on three main areas: Colorectal Cancer Screening, MCED Test Development and MRD Test Development. The Company's products and services include Cologuard test, Oncotype DX Breast Recurrence Score Test, Oncotype DX Breast DCIS Score Test, Oncotype DX Colon Recurrence Score Test, and OncoExTra Test. The Company's flagship screening product, the Cologuard test, is a non-invasive, stool-based deoxyribonucleic acid (sDNA) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Oncotype DX Breast Recurrence Score test examines the activity of 21 genes in a patient's breast tumor tissue.
Financial Overview
For the fiscal year ended 31 December 2023, Exact Sciences Corp revenues increased 20% to $2.5B. Net loss decreased 67% to $204.1M. Revenues reflect Commercial segment increase of 27% to $1.17B, Medicare Parts B & C segment increase of 20% to $890.1M, United States (Country) segment increase of 19% to $2.35B, Outside of united states segment increase of 30% to $153.3M.
Employees: 6,500 as of Dec 31, 2023
Reporting Currency: U.S. Dollars
Enterprise value: $13,130M as of Dec 31, 2023
Annual revenue (TTM): $2,500M as of Dec 31, 2023
EBITDA (TTM): -$7.78M as of Dec 31, 2023
Net annual income (TTM): -$204.15M as of Dec 31, 2023
Free cash flow (TTM): $31.43M as of Dec 31, 2023
Net Debt Last Fiscal Year: $1,606M as of Dec 31, 2023
Shares outstanding: 181,530,967 as of Feb 20, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.